China and US Advance Joint Counternarcotics Efforts Amid Renewed Cooperation

Renewed Bilateral Cooperation

China and the United States have made notable progress in their joint efforts to combat illicit drugs, marking a significant resumption of cooperation between the two global powers. This advancement follows a consensus reached during the November 2023 summit between President Joe Biden and President Xi Jinping in San Francisco, which led to the re-establishment of a joint U.S.-China counternarcotics working group. The cooperation had previously been suspended in August 2022.

The re-creation of the working group was a key diplomatic breakthrough aimed at stabilizing the broader bilateral relationship. Officials from both nations have since engaged in frequent high-level exchanges and meetings to coordinate strategies against the global manufacturing and trafficking of synthetic drugs, especially fentanyl.

Key Initiatives and Meetings

The U.S.-China Counternarcotics Working Group officially launched in January 2024, holding its inaugural meeting on January 30. A senior official meeting of the group was subsequently held in Washington, D.C., on July 31, 2024. These discussions have centered on several critical areas:

• Strengthening coordination on law enforcement actions.
• Disrupting the illicit financing of transnational criminal organization networks.
• Accelerating the scheduling of synthetic drugs and precursor chemicals.
• Addressing the illicit diversion of precursor chemicals.
• Exchanging information on emerging threats.
• Advancing progress in multilateral forums.

High-level engagements in 2024 included meetings between Chinese State Councilor and Minister of Public Security Wang Xiaohong and US Secretary of Homeland Security Alejandro Mayorkas, as well as with Rahul Gupta, Director of the White House Office of National Drug Control Policy.

Tangible Results and Joint Investigations

The renewed collaboration has already yielded concrete results. On August 5, 2024, China announced the scheduling of three essential fentanyl precursors, following an earlier announcement in early August 2024 regarding the control of three precursor chemicals used in fentanyl production. Additionally, China expanded its list of controlled psychoactive substances in 2024.

Joint investigations have also seen progress. In June 2024, Chinese police initiated an investigation into illegal foreign exchange transactions based on intelligence provided by the U.S. regarding drugs and money laundering. Furthermore, China announced the arrest of an individual on June 18, 2024, who had been indicted in the U.S. for involvement in a money laundering scheme linked to the Sinaloa cartel.

A significant trilateral law enforcement operation involving China, Thailand, and the U.S. took place in February 2025. Acting on intelligence from the U.S. Drug Enforcement Administration (DEA), Chinese narcotics control and coast guard authorities conducted a maritime operation near Huangyan Island in the South China Sea. This operation resulted in the capture of seven suspects and the seizure of nearly 5,000 kilograms of methamphetamine, marking the largest single maritime drug bust in the Asia-Pacific region in recent years.

Looking Ahead

While the resumption of cooperation is a positive step, some experts maintain a degree of skepticism regarding the long-term impact and the extent of China's commitment, citing past challenges in enforcement. Historically, China was a primary source of finished fentanyl until 2019, after which production largely shifted to Mexico, though precursor chemicals continue to originate from China. Both nations continue to emphasize the importance of sustained dialogue and mutual respect in addressing prominent global drug-related challenges.